Otero ORR, Moragues MJR, Ávila OE, Contreras ED, Paniagua OMJ, Barragán SA, Reyes CAF, Cabrera LCF, Fernández MM, Morales-Blanhir JE

Language: Spanish
References: 22
Page: 178-185
PDF size: 197.59 Kb.

ABSTRACT

The Goodpasture’s syndrome is a rare autoimmune disease, with an incidence of 0.1 person per million, considered as a hypersensibility disease which etiology is unknown. It consists of three characteristics, pulmonary hemorrhages, proliferative glomerulonephritis, and anti-glomerular basement membrane antibody which react to the noncollagenous domain of the alpha 3 chain of collagen type IV. In order to make the clinic diagnostic, the presence of renal and pulmonary manifestations is necessary. The pulmonary manifestations are usually found before renal manifestations, among them hemoptysis being the most common. Treatment of this disease has suffered modifications with the development of new techniques, and is headed towards the control of the bleeding complications, such as anemia or hemodynamic instability, and the dropdown of circulating antibodies, mainly by the use of immune suppressors and plasmapheresis. Evaluating the prognosis of this disease gives very little evidence, that’s why it is impossible to establish in a clear way, however most patients will progress invariably to terminal renal insufficiency.

REFERENCES

1. Pierson DJ. Respiratory considerations in the patient with renal failure. Resp Care 2006; 51(4): 413-422.

2. Jung C, Karpouzas G, Stringer WW. Dyspnea, hemoptysis, and perihilar infiltrates in a 35-year-old man, MD, FCCP. Chest 2005; 127(4) 1437-1441.

3. Goldman. Cecil Textbook of Medicine, 22nd ed. W. B. Saunders Company. Copyright © 2004.

4. Mason. Murray & Nadel’s Textbook of Respiratory Medicine. 4th ed. Copyright © 2005.

5. Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004: 2514-27.

6. Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med 2004: 583-92.

7. Greenberg A. Tratado de enfermedades renales. Editorial Harcourt Brace 1999.

8. Álvarez MJ. Manual Merck, Harcourt, Ed. 10.

9. Abbas AK. Inmunología celular y molecular. Saunders Elsevier 2004.

10. Farreras. Medicina interna. Ed. 14.

11. Robbins. Patología estructural y funcional. 7 ed. Kumar, Vinay. Editorial Harcourt Brace-Elsevier 2005.

12. Peña RJC. Manual de nefrología y trastornos de agua y electrolitos. McGraw-Hill, Agosto 2005.

13. Cairns LS. The fine specificity and cytokine profile of T helper cells responsive to the a3 chain of type IV collagen in Goodpasture´s disease. J Am Soc Nephrol 2003; 14: 2801-12.

14. Brenner & Rector’s, The Kidney, 7th ed. Saunders. Elsevier. Copyright © 2004.

15. Harrison. Principios de medicina interna. 2 Vols. Edición 16ª. Ed. McGraw-Hill 2006.

16. Bergs L, RN, BSN, CNN; Goodpasture Syndrome; Immunology.

17. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 11: 1033-42.

18. Fort J, Espinel E, Rodriquez JA, Curull V, Madrenas J, Piera L. Partial recovery of renal function in an oligoanuric patient affected with Goodpasture’s syndrome after treatment with steroids, immunosuppressives and plasmapheresis. Clin Nephrol 1984; 22: 211-2.

19. 19 Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61: 922-4.

20. 20 Hind CR, Paraskevakou H, Lockwood CM, Evans DJ, Peters DK, Rees AJ. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1983; 1(8319): 263-5.

21. 21 Garcia-Canton C, Toledo A, Palomar R, et al. Goodpasture’s syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant 2000; 15: 920-2.

22. 22 Gallagher H. Pulmonary renal syndrome: A 4 year center experience. American Journal of Kidney Diseases 2002: 42-7.